- Tiens Biotech Group
-
Tiens Biotech 
Type Pharmaceutical Industry Pharmaceuticalhgjjhhgj Founded 1998 Headquarters Tianjin, People's Republic of China Area served People's Republic of China Key people Jinyuan Li, CEO
Dr. Wenjun Jiao, CFO
Eric Doering, General Counsel
Yupeng Yan, VP HR, Admin
Ping Bai, Exec. Asst. to President
Cindy Lu, Secretary
Socorro M. Quintero, Director
Howard R. Balloch, Director
Gilbert D. Raker, DirectorProducts Pharmaceutical
nutrition supplementRevenue 
$77.2 million USD (2008)Net income $27.7 million USD (2008)Employees 1,549 (31st December, 2008) Subsidiaries Tianjin Tianshi Biological Development Co., Ltd.
Tiens Yihai Co., Ltd.Website www.tiens.com Tiens Biotech Group USA Inc., (AMEX: TBV), operates primarily through its China-based subsidiary Tiens Biological Development CO. Ltd. Tiens Biological has developed and produced seven major product series, of which six comprise nutrition supplement products, and the seventh comprises personal care products. It develops its products at its own product research and development center and conducts the marketing and sales of its products through its affiliated company, which owns 23 branches, representative offices and chain stores. The company's stock is traded on the American Stock Exchange. On its initial IPO, entering public market with offering price of USD12/share has inflate Tiens value however as time goes by, the share value is continously drop to USD 1.32/share (May 2011).
Contents
Joint venture
The company entered into a joint venture with Tianjin Tianshi Pharmaceutical Co., Ltd. in 2004 :
In April 2004 Tiens' wholly owned subsidiary, Tianshi International Holding Group Ltd. entered into a joint venture agreement with Tianjin Tianshi Pharmaceutical Co., Ltd. to establish Tiens Yihai, a Chinese-Foreign Equity Joint Venture. Located in Shanghai,China, Tiens Yihai is in the business of research and development, production and marketing of nutrition supplements products, home care and personal care products. The total investment amount is projected to be approximately $40 0million.
Tiens Yihai Co. Ltd. holds land use rights for 50 acres (200,000 m2) of land located in Shanghai, China. Tiens Yihai Co. Ltd. was established to build a new research and development facility. In March 2007, Tiens Biotech Group (USA), Inc. decided to suspend the proposed development by Tiens Yihai due to financial difficulties.
On November 15, 2009, Tianshi International Holdings Group Ltd. agreed to sell all of the registered share capital of Tiens Yihai Co. Ltd. it owns to Tianshi International Investment Group Co., Ltd.
Jinyuan Li, the Chairman, Chief Executive Officer and President of Tiens Biotech Group (USA), Inc., owns 100% of Tianshi International Investment Group Co., Ltd.
Tianshi International Holdings Group Ltd. holds 96% of the equity interest in Tiens Yihai Co. Ltd. Tianjin Tianshi Pharmaceuticals Co., Ltd. owns the remaining 4% of Tiens Yihai’s share capital.
The transaction is expected to be closed by December 2009, subject to approval by the appropriate examination and approval authority of the People’s Republic of China to record the equity transfer.
Pursuant to the Agreement, the total purchase price of $37,000,000 for the acquisition will be payable as follows: (i) $3,700,000 by January 14, 2010 and (ii) $33,300,000 by November 14, 2010.
References
- [1] 2008 Annual Report.
- [2] SEC filing detailing Tiens Yihai Co. Ltd. stake transfer to Tianshi International Investment Group Co., Ltd.
External links
- Tiens Group. Official site
- New biz model paving the way to success, China Daily, November 3, 2006
- Tiens (TBV.A) shares value in stock exchange
- Tiens Performance in Indonesia, report in Asian Language , Jan 2009
- Tiens in Serbia
- Tiens in Tibet
See also
Categories:- Companies listed on the American Stock Exchange
- Pharmaceutical companies of the United States
- Medical company stubs
- Chinese company stubs
Wikimedia Foundation. 2010.
